USMIRC News
@USMIRCNEWS
Followers
159
Following
769
Media
117
Statuses
457
USMIRC news is media for plasma cell disorders, Myeloid and Lymphona news, blogs and updates #USMIRC #mmsm
Kansas City, MO
Joined November 2023
🎬 The latest 5th issue of USMIRC News is now out! Check out all the news we’ve got uploaded. . #MedEd #MedTwitter #USMIRC @USMIRCNEWS
0
3
5
RT @mumairmushtaq: TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care via @CancerNetwrk .@KUcanc….
cancernetwork.com
At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.
0
2
0
RT @mumairmushtaq: Cellular Therapies Hold Promise in The Future of Melanoma Care via @CancerNetwrk .@KUcancercent….
cancernetwork.com
“It’s a treatment for those patients who don’t have any other effective treatments available,” said Muhammad Umair Mushtaq, MD, on lifileucel in melanoma.
0
1
0
RT @mumairmushtaq: TIL Therapy Holds Potential for Growth in Advanced Melanoma via @@CancerNetwrk.@KUcancercenter….
cancernetwork.com
“There is margin to improve on these treatments, but this is a real hope for patients with melanoma,” said Mushtaq on TIL therapies.
0
2
0
RT @CancerNetwrk: At the 2025 ICE-T Symposium, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, spoke with us about some of the most exciting….
cancernetwork.com
The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.
0
2
0
RT @Abdallah81MD: In a conversation with CancerNetwork® at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference, Tiba Al Saghe….
0
3
0
RT @Abdallah81MD: 📣 Mark your calendars!.Join us for the 2nd Regional ICE-T Congress 🧊.📅 September 27–28, 2025.📍 Kansas City, Kansas. ✨ Whe….
0
3
0
RT @CancerNetwrk: Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs….
cancernetwork.com
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
0
3
0
RT @CancerNetwrk: "There needs to be cross-collaboration…such that, on the hematology side, we help our oncology colleagues with the unique….
cancernetwork.com
The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.
0
3
0
RT @JanakiramMurali: We want to share this important toxicity profile of GPRC5D BisAb- Talquetamab. GPRC5D Bispecific antibody talquetamab….
0
29
0
RT @myelomadoctor: Great to present at #davaheme on safely administering bispecifics in the outpatient setting for RRMM. Covered patient se….
0
5
0
RT @Abdallah81MD: Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types. The 2025 National #ICE_T Symposium gave on….
0
3
0
RT @Abdallah81MD: 1/🔬 A Quick Look at JNJ-5322 Trispecific Antibody Study (Baseline Data): Both sides Good and Bad! 🧵. Phase 1 trial inves….
0
8
0
0
1
0
RT @CancerNetwrk: "However, we must always be careful when you use MRD as an end point because patients with high-risk disease could relaps….
cancernetwork.com
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
0
1
0
RT @CancerNetwrk: More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, acc….
0
3
0
"As a course director for the ICE-T symposium, the whole ICE-T concept was to bring our academic knowledge and our academic leaders [together] with community leaders to try and get increased access out in the community," said Nausheen Ahmed, MD. @CancerNetwrk @NausheenAhmedMD.
1
2
4
RT @Abdallah81MD: From @CancerNetwrk during the National #ICE_T conference: Developing a Bridge to Optimize Cellular Therapy Use in Multipl….
0
2
0
RT @Abdallah81MD: 🎙️ Highlight from #ICE_T2025.CancerNetwork (@CancerNetwrk) spoke with Dr. Nausheen Ahmed (@NausheenAhmedMD) at the inaugu….
0
5
0
At the National #ICE_T conference, Barry Paul, MD highlighted cilta-cel, anito-cel & arlo-cel as leading CAR T-cell therapies in multiple myeloma—delivering deep remissions. #MultipleMyeloma #CARTcell.@CancerNetwrk #mmsm .
cancernetwork.com
Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.
0
0
3